Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer
出版年份 2022 全文链接
标题
Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer
作者
关键词
-
出版物
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-06-15
DOI
10.1038/s41401-022-00930-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer
- (2021) Xing-mei Liang et al. ACTA PHARMACOLOGICA SINICA
- Cystine supplementation rebalances the redox homeostasis of microenvironment in non-small cell lung cancer cells and reverses their resistance to docetaxel
- (2021) Si-jia Li et al. ACTA PHARMACOLOGICA SINICA
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Boronic acid with high oxidative stability and utility in biological contexts
- (2021) Brian J. Graham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
- (2021) Min Luo et al. Acta Pharmaceutica Sinica B
- PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway
- (2021) Mei-sa Wang et al. ACTA PHARMACOLOGICA SINICA
- Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
- (2021) Jamie E. Chaft et al. Nature Reviews Clinical Oncology
- An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness
- (2021) Lei Liu et al. Nature Communications
- GSH-sensitive polymeric prodrug: Synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine
- (2021) Lei Luo et al. Acta Pharmaceutica Sinica B
- Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
- (2021) Mingming Zhang et al. Acta Pharmaceutica Sinica B
- Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
- (2021) Umair Majeed et al. Journal of Hematology & Oncology
- Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer
- (2021) Lei Fang et al. Acta Pharmaceutica Sinica B
- New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer
- (2020) Huiping Qiang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Development of amine-functionalized superparamagnetic iron oxide nanoparticles anchored graphene nanosheets as a possible theranostic agent in cancer metastasis
- (2020) Mahesh P. More et al. Drug Delivery and Translational Research
- HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells
- (2020) Qian Liang et al. ACTA PHARMACOLOGICA SINICA
- Application of targeted therapy strategies with nanomedicine delivery for atherosclerosis
- (2020) Le-chun Ou et al. ACTA PHARMACOLOGICA SINICA
- The EZH2-PHACTR2-AS1-ribosome axis induces genomic instability and promotes growth and metastasis in breast cancer
- (2020) Wenhui Chu et al. CANCER RESEARCH
- NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
- (2020) Makoto Maemondo et al. JOURNAL OF CLINICAL ONCOLOGY
- MDL-800, an allosteric activator of SIRT6, suppresses proliferation and enhances EGFR-TKIs therapy in non-small cell lung cancer
- (2020) Jia-lin Shang et al. ACTA PHARMACOLOGICA SINICA
- Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook
- (2020) Josep Garcia et al. CANCER TREATMENT REVIEWS
- The Effect of Advances in Lung-Cancer Treatment on Population Mortality
- (2020) Nadia Howlader et al. NEW ENGLAND JOURNAL OF MEDICINE
- The progress and perspective of nanoparticle-enabled tumor metastasis treatment
- (2020) Wei Zhang et al. Acta Pharmaceutica Sinica B
- Molecular engineering of antibodies for site-specific conjugation to lipid polydopamine hybrid nanoparticles
- (2020) Hobin Yang et al. Acta Pharmaceutica Sinica B
- Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer
- (2020) Rong Wang et al. Nature Communications
- VEGFR2-targeted antibody fused with IFN mut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity
- (2020) Pengzhao Shang et al. Acta Pharmaceutica Sinica B
- GSH-responsive SN38 dimer-loaded shape-transformable nanoparticles with iRGD for enhancing chemo-photodynamic therapy
- (2020) Congcong Lin et al. Acta Pharmaceutica Sinica B
- Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab
- (2020) Doan T. M. Ngo et al. Journal of Clinical Medicine
- The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer
- (2020) Chao Zhao et al. Translational Lung Cancer Research
- Role of Glutathione in Cancer: From Mechanisms to Therapies
- (2020) Luke Kennedy et al. Biomolecules
- Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype
- (2020) Monique B. Nilsson et al. Journal of Thoracic Oncology
- Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
- (2020) Antonio Passaro et al. Journal of Thoracic Oncology
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy
- (2019) Ang Gao et al. ACTA PHARMACOLOGICA SINICA
- Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors
- (2019) Terrick Andey et al. Nanomedicine-Nanotechnology Biology and Medicine
- Engineering nanoparticles to locally activate T cells in the tumor microenvironment
- (2019) Dangge Wang et al. Science Immunology
- Corona Composition Can Affect the Mechanisms Cells Use to Internalize Nanoparticles
- (2019) Valentina Francia et al. ACS Nano
- 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study
- (2019) Yung-Hung Luo et al. LANCET ONCOLOGY
- Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer
- (2019) Thomas E. Stinchcombe et al. JAMA Oncology
- A Nanoemulsion with A Porphyrin Shell for Cancer Theranostics
- (2019) Wenxiu Hou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- 1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
- (2019) Q Zhou et al. ANNALS OF ONCOLOGY
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- Overview of current systemic management of EGFR-mutant NSCLC
- (2018) W -H Hsu et al. ANNALS OF ONCOLOGY
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy
- (2018) Bingjun Sun et al. NANO LETTERS
- Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
- (2018) Rajeswara Rao Arasada et al. Nature Communications
- The architecture of EGFR’s basal complexes reveals autoinhibition mechanisms in dimers and oligomers
- (2018) Laura C. Zanetti-Domingues et al. Nature Communications
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy
- (2017) Qingle Song et al. NANO LETTERS
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- Proteome- pI : proteome isoelectric point database
- (2016) Lukasz P. Kozlowski NUCLEIC ACIDS RESEARCH
- Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
- (2016) A Dokala et al. ONCOGENE
- Impact of bevacizumab in combination with erlotinib onEGFR-mutated non-small cell lung cancer xenograft models with T790M mutation orMETamplification
- (2015) Koh Furugaki et al. INTERNATIONAL JOURNAL OF CANCER
- IL-6 Antibody and RGD Peptide Conjugated Poly(amidoamine) Dendrimer for Targeted Drug Delivery of HeLa Cells
- (2015) Shewaye Lakew Mekuria et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Principles of nanoparticle design for overcoming biological barriers to drug delivery
- (2015) Elvin Blanco et al. NATURE BIOTECHNOLOGY
- Cationic Bovine Serum Albumin Based Self-Assembled Nanoparticles as siRNA Delivery Vector for Treating Lung Metastatic Cancer
- (2013) Jianfeng Han et al. Small
- Interaction of nanoparticles with proteins: relation to bio-reactivity of the nanoparticle
- (2013) Shruti R Saptarshi et al. JOURNAL OF NANOBIOTECHNOLOGY
- Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
- (2012) S Yoshikawa et al. ONCOGENE
- EGFR Mutations and Lung Cancer
- (2011) Gilda da Cunha Santos et al. Annual Review of Pathology-Mechanisms of Disease
- DNA affects the composition of lipoplex protein corona: A proteomics approach
- (2011) Anna L. Capriotti et al. PROTEOMICS
- Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions
- (2009) Janos Szebeni et al. JOURNAL OF LIPOSOME RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started